Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged CEO, CEOs, drug safety, Eli Lilly, Global, healthcare reform, innovation, IP, IPAB, Lilly, PhRMA, policy, R&D
PharmExec Blog
Follow Us
RSS
Bookstore
Fixing Innovation: Lilly's CEO Says Why, and How